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Abstract
Purpose To analyse the complication outcomes of COVID-19 negative patients undergoing elective head and neck surgery 
during the COVID-19 pandemic.
Methods This was a retrospective case review of all patients undergoing elective head and neck surgery for confirmed or 
suspected head and neck cancer.
Results There were no mortalities recorded in the cohort of patients analysed. At 30 days, pulmonary complications had 
occurred in 4 patients (9%). None of these were related to COVID infection.
Conclusion With careful pre-operative screening of patients for COVID-19 and post-operative care in a COVID-19 clean 
ward, head and neck surgery can proceed safely during the epidemic. This data could help to minimise delay in treatment 
by allowing a greater number of elective head and neck cancer operations to proceed.
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Introduction
Coronavirus (COVID-19), the novel disease caused by the 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), was declared a pandemic by the World Health 
Organisation in March 2020 [1]. There have been over 
7,250,000 confirmed cases worldwide and to date, over 
400,000 people have died as a result of the disease [1]. The 
disease outbreak has tested the resilience of global health-
care services.
Our institution is a tertiary centre for head and neck 
cancer and documented its first coronavirus deaths on 
the 12th March 2020. Within 8 days, the total number of 
patient deaths in this hospital accounted for 1/5th of all 
deaths recorded in London [2]. By mid-April, London was 
the worst hit region in the United Kingdom, recording the 
highest age-adjusted mortality rate in the country (85.7 per 
100,000 deaths related to COVID-19) [3].
In response to the pandemic, a dramatic and unprec-
edented change to clinical practice has necessarily been 
implemented. Primarily, this has been to increase inpatient 
capacity to meet the demands created by the acute surge in 
COVID-19 patients, many of whom require ventilated beds 
in an intensive care setting. This requires staff re-alloca-
tion away from normal surgical duties. Furthermore, early 
published data have suggested that the 30-day mortality 
and morbidity were significantly higher in patients under-
going both elective and emergency surgery when SARS-
CoV-2 infection was confirmed perioperatively [4]. For 
these reasons, NHS England and other professional bodies 
worldwide have issued guidance on how best to prioritise 
patients undergoing surgery during this time. As a result of 
the above, our institution acted to limit all ‘non-essential’ 
surgery, thereby minimising the risk of in-hospital COVID-
19 transmission, as well as any post-operative pulmonary 
complications that may ensue [5–7].
Sadly, delaying elective surgery will have a signifi-
cant negative impact on both patients and healthcare sys-
tems worldwide. Whilst many elective operations can be 
delayed, the treatment of many head and neck cancers can-
not be safely deferred. Any delay in such patients’ cancer 
must be weighed against associated increased morbidity and 
mortality.
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Herein, we present the complication outcomes of patients 
undergoing elective head and neck surgery for confirmed or 
suspected cancer during the COVID-19 pandemic in a hospi-
tal treating a high volume of COVID-19 patients. This study 
reports on the 30-day mortality and morbidity of elective 
head and neck surgery, including both the rate of pulmonary 
and non-COVID-19-related complications. This data pro-
vides a baseline from which hospitals can plan their post-
pandemic surgical recovery. There has been only one similar 
small study published in the literature that investigated the 
outcome of three patients undergoing elective head and neck 
surgery during the COVID-19 pandemic [8].
Methods
Study design
This was a retrospective case review of all patients under-
going elective head and neck surgery for confirmed or sus-
pected head and neck cancer.
Study population
All patients undergoing elective head and neck surgery for 
confirmed or suspected cancer at our institution over an 
8-week period (23rd March–20th May 2020) were included 
in this study. The hospital’s Standard Operative Procedure 
(SOP) (dated 1st May 2020) stated that all patients under-
going elective surgery had to confirm if they were unwell, 
exhibited any COVID-19 symptoms or had been in close 
contact with a person with symptoms. Patients were advised 
to self-isolate for 14 days prior to surgery. A nasopharyn-
geal swab was taken 48 h prior to admission. On the day 
of surgery, patients underwent chest radiography (CXR), 
which was reported by a radiologist. Perioperatively, patients 
remained in a designated COVID ‘green’ part of the hospi-
tal, where all patients had a COVID-negative swab and were 
asymptomatic for COVID symptoms. Prior to 1st May 2020, 
there was no formal SOP but our unit’s practice was similar.
Exclusion criteria
Patients undergoing procedures under local anaesthetic, 
trauma/emergency surgery or other otolaryngological pro-
cedures were not included.
Variables
The primary outcome measure was 30-day mortality of 
patients undergoing surgery. The secondary outcome meas-
ure was 30-day morbidity including pulmonary and other 
post-operative complications. Pulmonary complications 
were defined as atelectasis, pneumonia, acute respiratory 
distress syndrome and post-operative ventilation (non-inva-
sive/invasive) that was not expected as part of the normal 
post-operative course. Post-operative complications were 
graded using the head and neck modified Clavien–Dindo 
classification [8]. Only routine anonymised data were 
collected.
Results
A total of 47 patients were included in the final analysis. 
Patient demographics including age, sex, co-morbidities and 
ASA (American Society of Anaesthesiologists physical sta-
tus classification) were recorded [9] (Table 1). Pre-surgery 
COVID symptoms and status were analysed—no patients 
reported any pre-operative COVID symptoms (defined 
as cough and/or fever, shortness of breath and myalgia). 
Accordingly, all of the patients were assumed to be COVID-
19 negative; this was supported by a negative swab in 81% of 
the patients (Table 2). The remaining 19% of patients were 
operated on prior to our hospital’s SOP, which stated that a 
swab and CXR must be taken prior to surgery.
There were no mortalities recorded in the cohort of 
patients analysed (Table 1). At 30 days, pulmonary com-
plications had occurred in four patients (9%). None of these 
were related to COVID infection (Table 3). Three of the 
patients who suffered pulmonary complications were male; 
they were all over the age of 50 with at least one co-morbid-
ity that included being a current/ex-smoker.
30-day morbidity for non-pulmonary complications 
was recorded in eight patients (17%) (Table 4). They were 
equally distributed between males and females. 88% of the 
patients were aged 30–69.
Discussion
The COVID-19 pandemic has drastically changed clinical 
practice worldwide and the delivery of routine elective sur-
gery has been disrupted to protect patients and healthcare 
workers. It has been estimated that 28,404,603 operations 
globally could be postponed due to the COVID-19 pandemic 
[10]. Currently, there is no vaccination or cure for COVID-
19. Results from one recent English study revealed that only 
6.78% of the general population were positive for COVID-19 
antibodies and so it is likely that COVID-19 will continue to 
be problematic for the foreseeable future [11]. Key consid-
erations must be taken to allow for the resumption of elective 
services to help address the significant backlog of surgical 
work and potential harm to patients waiting for their delayed 
treatment [12].
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Initial analysis of patients undergoing elective surgery 
that were asymptomatic and not known to be infected with 
SARS-CoV-2 in China during the COVID-19 pandemic 
suggested that surgery may exacerbate COVID-19 disease 
progression. Lei et al. [13] demonstrated a mortality rate of 
20.5% in patients undergoing various planned operations and 
all patients went on to develop pneumonia. 30-day mortal-
ity and morbidity have been found to be significantly higher 
Table 1  Baseline demographic characteristics
Patient numbers 30-Day mortal-
ity (no. of 
patients)
30-Day pulmonary 
complications (no. of 
patients)
30-Day mor-
bidity (no. of 
patients)
Total patients 47 0 4 (9%) 8 (17%)
 Sex
  Male 31 (66%) 0 3 (6%) 4 (9%)
  Female 16 (34%) 0 1 (2%) 4 (9%)
Age (years)
  < 29 2 (4%) 0 0 0
 30–49 13 (28%) 0 0 3 (6%)
 50–69 24 (51%) 0 3 (6%) 4 (9%)
  > 70 8 (17%) 0 1 (2%) 1 (2%)
Number of co-morbidities
 0 13 (28%) 0 0 3 (6%)
 1 15 (32%) 0 2 (4%) 2 (4%)
 2 or more 19 (40%) 0 2(4%) 3 (6%)
ASA grade
 1 13 (28%) 0 0 1 (2%)
 2 26 (55%) 0 2 (4%) 6 (13%)
 3 6 (13%) 0 1 (2%) 1 (2%)
 4 2 (4%) 0 1 (2%) 0
Symptoms at admission
 None 47 (100%) 0 0 0
 Symptoms 0 0 0 0
Cancer stage
 Diagnostic surgery 19 (40%) 0 1 (2%) 4 (9%)
 1 11 (23%) 0 1 (2%) 0
 2 4 (9%) 0 1 (2%) 1 (2%)
 3 2 (4%) 0 0 0
 4 11 (23%) 0 1 (2%) 3 (6%)
Operation
 Panendoscopy ± tonsillectomy ± dental extractions 17 (36%) 0 1 (2%) 4 (8%)
 Wide local excision tongue/buccal mucosa ± neck dissection 11 (23%) 0 2 (4%) 1 (2%)
 Nasal biopsy ± debulking 7 (15%) 0 1 (2%)
 Total thyroidectomy + selective neck dissection 4 (9%) 0 1 (2%)
 Parotidectomy ± neck dissection 3 (6%) 0
 Trans oral robotic surgery + selective neck dissection 1 (2%) 0 1 (2%)
 Selective neck dissection 1 (2%) 0
 Excision lymph node 1 (2%) 0
 Major head and neck resection with free flap reconstruction 1 (2%) 0 1 (2%)
 Right partial maxillectomy + obturator insertion 1 (2%) 0
Table 2  Negative COVID-19 status confirmed with nasal swab and/
or CXR
COVID-19 status Total patients
Negative (swab and CXR) 22 (47%)
Negative (swab or CXR) 38 (81%)
No swab or CXR 9 (19%)
 European Archives of Oto-Rhino-Laryngology
1 3
(23.7% mortality and 50.9% pulmonary complications) in 
patients undergoing surgery (elective and emergency), when 
SARS-CoV-2 infection is confirmed perioperatively [4]. 
The most vulnerable patients have been identified as males 
over the age of 70 with co-morbidities, those undergoing 
cancer or other major surgery and patients requiring emer-
gency operations [4]. Patients with cancer are at an increased 
risk of contracting COVID-19 compared with non-cancer 
patients [14] and the rate of fatality amongst this patient 
cohort has been found to be 5.6% compared with 2.3% for 
the average population [15].
The impact of operating on non-coronavirus elective head 
and neck patients has not been notably analysed. However, 
as a result of published studies such as Lei et al. [13] and 
a paucity of local data regarding patient safety outcomes, 
thresholds for performing surgery during these times have 
been rightly scrutinised. This led to the NHS England guide-
line for the management of patients requiring surgery during 
the COVID-19 crisis. This document describes five priority 
levels and their corresponding action, to be decided by a 
consultant lead within each speciality [16]. At the peak of 
the COVID-19 pandemic, only priority level 1a, 1b and 2 
patients were permitted to undergo surgery nationally. This 
was supported by BAHNO, ENT UK and BAETS [17]. A 
comparable approach has been adopted by institutions in 
other countries such as France, USA and Australia [18–20] 
and has also been recommended by a consortium of interna-
tional clinical trials units, member organisations of the Head 
and Neck Cancer International Group [21].
The multidisciplinary management of head and neck can-
cer patients is complex. This cohort of patients is usually 
older and co-morbid, often with tobacco-related respiratory 
diseases, and therefore has a higher risk of developing severe 
post-operative complications both with and without SARS-
CoV-2 exposure and infection [8, 9]. Delaying treatment is, 
however, associated with disease progression and increased 
patient anxiety, which can negatively impact patient survival 
outcomes [9].
Our study analysed patient data over an 8-week period 
during the peak of the COVID-19 pandemic in a hospital 
treating a high number of patients infected with SARS-
CoV-2. The study identified that, in our case series, 
there was no 30-day mortalities related to COVID-19 or 
other causes in patients asymptomatic for SARS-CoV-2 
Table 3  30-day pulmonary complications following elective head and neck surgery
Sex Age Co-morbidities ASA COVID-19 
negative 
swab
Normal CXR Operation Pulmonary complication
M 54 Asthma, HTN, ex-smoker, COPD 3 Nil Nil Wide local excision tongue, 
selective neck dissection, radial 
forearm free flap
Bacterial pneumonia
M 68 Ex-smoker 2 Nil Yes Wide local excision buccal 
mucosa, selective neck dissec-
tion
Atelectasis
F 72 Smoker, OA, HTN, COPD 4 Negative (2) Yes Endoscopic debulking of left 
sinonasal mucosal melanoma
Bacterial pneumonia
M 62 Smoker 2 Negative (1) Yes Panendoscopy Saturations dropped 
88–92 (non-diagnosed 
COPD)
Table 4  30-day post-operative complications following elective head and neck surgery
Sex Age Co-morbidities ASA COVID-19 Nega-
tive swab
Normal CXR Post-operative complication (using the head and 
neck modified Clavien–Dindo classification [8]
M 67 T2DM, ex-smoker 3 Negative (2) Normal I
M 68 Ex-smoker 2 Nil Normal II
M 43 Nil 1 Negative (1) Nil II
F 46 Nil 2 Nil Nil II
M 70 AF 2 Negative (1) Nil III
F 37 Nil 2 Negative (1) Normal I
F 67 Smoker, GORD, high 
cholesterol
2 Nil Normal II
M 54 Ex-smoker, HTN 2 Negative (1) Normal II
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infection undergoing elective head and neck surgery. 81% 
of the patients were confirmed to be negative for SARS-
CoV-2 infection perioperatively through swab testing or 
CXR. The remaining 19% did not have confirmed evi-
dence of COVID-19 status in their documentation; how-
ever, they underwent surgery as no symptoms of COVID-
19 or contact with anyone with symptoms was reported 
pre-operatively.
Furthermore, the study did not demonstrate any nota-
ble risk of 30-day pulmonary complications—9% of the 
patients analysed had a documented lung complication 
post-operatively. No complication was COVID-19 related; 
no patients tested positive for SARS-CoV-2 infection post-
operatively. At the time of analysis, no patient remained in 
hospital following surgery. This has a significant implica-
tion for clinical practice, as it is evidence from a London 
teaching hospital and acute medical admission and trauma 
unit at the epicentre of the COVID-19 pandemic. The data 
can be interpreted and used to balance the risk of delaying 
elective surgery versus proceeding with operating on head 
and neck cancer patients.
Study limitations
There are limitations to recognise when interpreting the data 
presented in this study. Although all patients undergoing 
elective head and neck surgery were included, the sample 
size was relatively limited. Baseline patient demographics 
were analysed; however, ethnicity was not included. This is 
important because black, Asian and minority ethnic groups 
have been found to have a markedly higher vulnerability and 
risk of mortality from COVID-19 [22].
Lastly, a nasopharyngeal swab, and/or CXR was used as 
means of determining pre-operative SARS-CoV-2 infec-
tion status. The benefit of testing patients however relies 
on the accuracy of the test and current literature states that 
the exact sensitivity and specificity for diagnosing infec-
tion with SARS-CoV-2 in unknown [23]. The recent intro-
duction of antibody testing may form an important part of 
pre-surgery assessment, in conjunction with or replacing 
the nasopharyngeal COVID-19 swab. Mounting an anti-
body response is however host-dependent and studies have 
shown that the average time a patient takes to seroconvert 
SARS-CoV-2 infection is 7–11 days [24]. Antibody testing 
is, therefore, not useful to determine acute infection status. 
Similarly, it is not yet known whether people who have been 
infected with and recovered from SARS-CoV-2 are fully 
immune from further infection; however, in combination 
with a nasopharyngeal swab, antibody testing could form 
part of the COVID-19 ‘pandemic suppression campaign’ 
[24], enabling hospitals to move forward and perform sur-
gery in the absence of a COVID-19 vaccination or cure [24].
Conclusion
This study looks at surgical 30-day mortality and morbidity 
rates in COVID-19 negative patients undergoing elective 
diagnostic and major therapeutic head and neck oncological 
surgery. There was no recorded mortality or post-operative 
COVID-19 related complications in our case series. Our 
results suggest that, with careful pre-operative screening of 
patients for COVID-19 and post-operative care in a COVID-
19 clean ward, head and neck surgery can proceed safely 
during the epidemic. This data could help to minimise the 
delay in treatment by allowing a greater number of elective 
head and neck cancer operations to proceed.
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